MedPage Today (11/10, DePeau-Wilson) reports, “The belief that long-acting injectable (LAI) antipsychotics for schizophrenia should be reserved for patients with severe symptoms or adherence issues may be contributing to their underutilization,” researchers concluded in a 380-participant, “nationwide survey of psychiatric clinicians.” The survey study revealed that “low LAI prescribers were more likely to say these therapies should only be used for patients with more severe symptoms (50% vs 21% for high prescribers) or with adherence issues (82% vs 50%, respectively).” The findings were presented at the Neuroscience Education Institute Congress.
Related Links:
— MedPage Today (requires login and subscription)